UBS Group
LYEL icon

UBS Group’s Lyell Immunopharma LYEL Stock Holding History

UBS Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Sell
25,982
-5,832
-18% -$106K ﹤0.01% 6434
2026
Q1 		$638K Buy
31,814
+18,611
+141% +$435K ﹤0.01% 5897
2025
Q4 		$406K Sell
13,203
-8,039
-38% -$180K ﹤0.01% 6203
2025
Q3 		$345K Sell
21,242
-4,392
-17% -$50.2K ﹤0.01% 6347
2025
Q2 		$227K Buy
25,634
+20,114
+364% +$183K ﹤0.01% 6638
2025
Q1 		$59.4K Sell
5,520
-37,694
-87% -$462K ﹤0.01% 7448
2024
Q4 		$553K Buy
43,214
+37,778
+695% +$749K ﹤0.01% 5770
2024
Q3 		$150K Buy
5,436
+1,195
+28% +$35.1K ﹤0.01% 6071
2024
Q2 		$123K Sell
4,241
-5,718
-57% -$272K ﹤0.01% 6033
2024
Q1 		$444K Sell
9,959
-983
-9% -$42.1K ﹤0.01% 5291
2023
Q4 		$425K Buy
10,942
+1,188
+12% +$42.8K ﹤0.01% 5227
2023
Q3 		$287K Buy
9,754
+2,095
+27% +$99.5K ﹤0.01% 5089
2023
Q2 		$487K Sell
7,659
-3,405
-31% -$188K ﹤0.01% 4847
2023
Q1 		$522K Sell
11,064
-9,487
-46% -$507K ﹤0.01% 4652
2022
Q4 		$1.43M Buy
20,551
+19,535
+1,923% +$1.94M ﹤0.01% 3729
2022
Q3 		$149K Buy
1,016
+755
+289% +$102K ﹤0.01% 5361
2022
Q2 		$34K Buy
261
+11
+4% +$1.12K ﹤0.01% 6264
2022
Q1 		$25K Sell
250
-470
-65% -$56.9K ﹤0.01% 7194
2021
Q4 		$112K Buy
720
+707
+5,438% +$158K ﹤0.01% 6213
2021
Q3 		$4K Buy
+13
New +$3.9K ﹤0.01% 8652

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

UBS Group's LYEL Position: Q2 2026 in Review

UBS Group reduced its Lyell Immunopharma (LYEL) stake by 18% in Q2 2026, selling an estimated $106K and leaving 25,982 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #6434.

UBS Group first reported a position in LYEL in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.43M in Q4 2022. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • UBS Group held 25,982 shares of Lyell Immunopharma worth $365K as of Q2 2026.
  • UBS Group sold 5,832 Lyell Immunopharma shares in Q2 2026, an estimated $106K.
  • Lyell Immunopharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6434 holding.
  • UBS Group first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 20 quarters since.
  • UBS Group's Lyell Immunopharma position peaked at $1.43M in Q4 2022.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.